Abstract
Systemic administration of local anesthetics has beneficial perioperative properties and an anesthetic-sparing and antiarrhythmic effect, although the detailed mechanisms of these actions remain unclear. In the present study, we investigated the effects of a local anesthetic, lidocaine, on hyperpolarization-activated and cyclic nucleotide-gated (HCN) channels that contribute to the pacemaker currents in rhythmically oscillating cells of the heart and brain. Voltage-clamp recordings were used to examine the properties of cloned HCN subunit currents expressed in Xenopus laevis oocytes and human embryonic kidney (HEK) 293 cells under control condition and lidocaine administration. Lidocaine inhibited HCN1, HCN2, HCN1-HCN2, and HCN4 channel currents at 100 μM in both oocytes and/or HEK 293 cells; it caused a decrease in both tonic and maximal current (∼30–50% inhibition) and slowed current activation kinetics for all subunits. In addition, lidocaine evoked a hyperpolarizing shift in half-activation voltage (ΔV1/2 of ∼−10 to −14 mV), but only for HCN1 and HCN1-HCN2 channels. By fitting concentration-response data to logistic functions, we estimated half-maximal (EC50) concentrations of lidocaine of ∼30 to 40 μM for the shift in V1/2 observed with HCN1 and HCN1-HCN2; for inhibition of current amplitude, calculated EC50 values were ∼50 to 70 μM for HCN1, HCN2, and HCN1-HCN2 channels. A lidocaine metabolite, monoethylglycinexylidide (100 μM), had similar inhibitory actions on HCN channels. These results indicate that lidocaine potently inhibits HCN channel subunits in dose-dependent manner over a concentration range relevant for systemic application. The ability of local anesthetics to modulate Ih in central neurons may contribute to central nervous system depression, whereas effects on If in cardiac pacemaker cells may contribute to the antiarrhythmic and/or cardiovascular toxic action.
Footnotes
This work was supported by the National Natural Science Foundation of China [Grant 30772076]; the 2009 National Alliance for Research on Schizophrenia and Depression Young Investigator Award Program; and the National Institutes of Health National Institute of General Medical Sciences [Grant GM66181].
Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.
doi:10.1124/mol.110.070227.
-
ABBREVIATIONS:
- HCN
- hyperpolarization-activated and cyclic nucleotide-gated
- MEGX
- monoethylglycinexylidide
- HEK
- human embryonic kidney
- I-V
- current-voltage.
- Received November 30, 2010.
- Accepted February 8, 2011.
- Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|